000281737 001__ 281737
000281737 005__ 20251013100037.0
000281737 0247_ $$2doi$$a10.1016/j.expneurol.2025.115491
000281737 0247_ $$2pmid$$apmid:41047113
000281737 0247_ $$2ISSN$$a0014-4886
000281737 0247_ $$2ISSN$$a1090-2430
000281737 037__ $$aDZNE-2025-01170
000281737 041__ $$aEnglish
000281737 082__ $$a610
000281737 1001_ $$aMöller, Meret$$b0
000281737 245__ $$aNetwork mechanisms in rapid-onset dystonia-parkinsonism.
000281737 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2025
000281737 3367_ $$2DRIVER$$aarticle
000281737 3367_ $$2DataCite$$aOutput Types/Journal article
000281737 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1760342324_8167
000281737 3367_ $$2BibTeX$$aARTICLE
000281737 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281737 3367_ $$00$$2EndNote$$aJournal Article
000281737 520__ $$aRapid-onset dystonia-parkinsonism (RDP) is a rare neurological disorder caused by mutations in the ATP1A3 gene. Symptoms are characterized by a dystonia-parkinsonism. Recently, experimental studies have shown that the pathophysiology of the disease is based on a combined dysfunction of the cerebellum (CB) and basal ganglia (BG) and that blocking their interaction can alleviate the symptoms. The underlying network mechanisms have not been studied so far. Our aim was to characterize neuronal network activity in the BG and CB and motor cortex in the ouabain model of RDP by site-specific infusion of ouabain. Rats were chronically infused with ouabain either in the CB, striatum (STR) or at both places simultaneously. Motor behavior was scored using published rating systems. Parallel in vivo recordings of local field potentials (LFP) from M1, deep cerebellar nuclei (DCN) and substantia nigra reticulata (SNr) were performed. Data were compared to untreated controls. Ouabain infusion into the cerebellum produced severe dystonia that was associated with increased high-frequency gamma oscillations in the DCNs, which were subsequently transmitted to the BG and M1. Striatal infusion led to parkinsonism and elevated beta-oscillations in SNr that were transmitted to the CB and M1. The simultaneous application of STRs and CB with ouabain resulted in dystonia-parkinsonism and increased beta oscillations in BG, CB, and M1. We demonstrate that symptom-specific beta and gamma oscillations can be transmitted between the BG and CB, which is likely to be very important for the understanding of disease mechanisms.
000281737 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000281737 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281737 650_7 $$2Other$$aBeta oscillations
000281737 650_7 $$2Other$$aGamma oscillations
000281737 650_7 $$2Other$$aRapid-onset dystonia parkinsonism
000281737 7001_ $$aNieweler, Johanna A$$b1
000281737 7001_ $$aNikulin, Vadim V$$b2
000281737 7001_ $$0P:(DE-2719)9001486$$avan Riesen, Christoph$$b3$$eLast author$$udzne
000281737 773__ $$0PERI:(DE-600)1466932-8$$a10.1016/j.expneurol.2025.115491$$gVol. 395, p. 115491 -$$p115491$$tExperimental neurology$$v395$$x0014-4886$$y2025
000281737 8564_ $$uhttps://pub.dzne.de/record/281737/files/DZNE-2025-01170.pdf$$yRestricted
000281737 8564_ $$uhttps://pub.dzne.de/record/281737/files/DZNE-2025-01170.pdf?subformat=pdfa$$xpdfa$$yRestricted
000281737 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001486$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000281737 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000281737 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-31$$wger
000281737 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-31
000281737 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-31
000281737 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-31
000281737 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-31
000281737 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-31
000281737 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-31
000281737 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-31
000281737 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-31
000281737 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-31
000281737 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEXP NEUROL : 2022$$d2024-12-31
000281737 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-31
000281737 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-31
000281737 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEXP NEUROL : 2022$$d2024-12-31
000281737 9201_ $$0I:(DE-2719)1410002$$kAG Fischer$$lEpigenetics and Systems Medicine in Neurodegenerative Diseases$$x0
000281737 980__ $$ajournal
000281737 980__ $$aEDITORS
000281737 980__ $$aVDBINPRINT
000281737 980__ $$aI:(DE-2719)1410002
000281737 980__ $$aUNRESTRICTED